Lead Sponsor

CytomX Therapeutics

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Histologically confirmed metastatic or locally advanced unresectable solid tumor. Must have received prior standard therapy.
•Measurable disease per RECIST 1.1
•Eastern Cooperative Oncology Group performance status of 0 or 1
•Adequate baseline laboratory values
•Patients of childbearing potential or those with partners of childbearing potential must agree to use a highly effective method of birth control from signing the ICF, and for a period of 30 days after the last dose of CX-904.

•History of malignancy that was active within the previous 2 years. Exceptions include localized cancers that are not related to the current cancer being treated, that are considered to have been cured, and in the opinion of the Investigator, present a low risk of recurrence
•Screening electrocardiogram demonstrating a mean QTcF value \> 480 msec; a screening echocardiogram with left ventricular ejection fraction (LVEF) \< 50%
•Serious concurrent illness
•History of or current active autoimmune diseases
•History of myocarditis regardless of the cause
•Pregnant or breast feeding